Faslodex (fulvestrant; AstraZeneca) is an analog of 17 beta-estradiol, the dominant circulating estrogen, which competitively inhibits the binding of natural estradiol to the estrogen receptor (ER). Estrogen controls the growth of many breast tumors. The binding of Faslodex to the ER impairs both receptor dimerization and ER nucleocytoplasmic shuttling, as well as accelerating degradation of the ER.
Faslodex (fulvestrant; AstraZeneca) will continue to see strong uptake in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer because of its demonstrated efficacy and a good tolerability profile. The drug’s potential as a combination therapy with approved cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor Ibrance (palbociclib; Pfizer), or any of several late-phase drug candidates, could increase uptake and boost sales in the future. Faslodex has also demonstrated an overall survival (OS) increase in a higher dosing regimen, joining Halaven (eribulin mesylate; Eisai) as the only approved therapies to do so in this indication to date.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Faslodex : Breast cancer: HR+/HER2
LIST OF FIGURES
14 Figure 1: Faslodex for HR+/HER2- breast cancer – SWOT analysis
15 Figure 2: Datamonitor Healthcare’s drug assessment summary of Faslodex in HR+/HER2-
16 Figure 3: Datamonitor Healthcare’s drug assessment summary of Faslodex in HR+/HER2-
LIST OF TABLES
4 Table 1: Faslodex drug profile
7 Table 2: Faslodex pivotal trial data in HR+/HER2- breast cancer
12 Table 3: Faslodex late-phase trial data in HR+/HER2- breast cancer
14 Table 4: Faslodex ongoing late-phase clinical trial in HR+/HER2- breast cancer
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.